E Fund Management’s Akero Therapeutics AKRO Stock Holding History

E Fund Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$555K	Buy	10,395 +3,471	+50%	+$158K	0.03%	215
2025 Q1	$280K	Buy	+6,924	New	+$293K	0.01%	323
2024 Q2	–	Sell	-13,899	Closed	-$351K	–	319
2024 Q1	$351K	Sell	13,899 -10,273	-42%	-$247K	0.02%	252
2023 Q4	$564K	Buy	24,172 +14,744	+156%	+$291K	0.04%	135
2023 Q3	$477K	Buy	9,428 +918	+11%	+$42.7K	0.04%	126
2023 Q2	$397K	Sell	8,510 -830	-9%	-$38K	0.03%	171
2023 Q1	$357K	Sell	9,340 -264	-3%	-$11.8K	0.03%	201
2022 Q4	$526K	Buy	+9,604	New	+$411K	0.04%	126

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E Fund Management's AKRO Position: Q2 2025 in Review

E Fund Management increased its Akero Therapeutics (AKRO) stake by 50% in Q2 2025, buying an estimated $158K and bringing the position to 10,395 shares worth $555K. The position accounts for 0.03% of the portfolio, ranked #215.

E Fund Management first reported a position in AKRO in Q4 2022 and has held it in 8 quarters since. The position peaked at $564K in Q4 2023. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

E Fund Management held 10,395 shares of Akero Therapeutics worth $555K as of Q2 2025.
E Fund Management bought 3,471 Akero Therapeutics shares in Q2 2025, an estimated $158K.
Akero Therapeutics made up 0.03% of E Fund Management's portfolio in Q2 2025, its #215 holding.
E Fund Management first reported a position in Akero Therapeutics in Q4 2022 and has held it in 8 quarters since.
E Fund Management's Akero Therapeutics position peaked at $564K in Q4 2023.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.